Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in Southeastern France

Journal of Medical Virology

Volumn 75, Issue 3, 2005, Pages 381-390

  Colson, Philippe ^a   Henry, Mireille ^a   Tivoli, Natacha ^a   Gallais, Hervé ^b   Gastaut, Jean Albert ^c   Moreau, Jacques ^d   Tamalet, Catherine ^a  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d HÔPITAL NORD   (France)

Author keywords

Drug resistance mutations; HIV 2; Natural polymorphism; Reverse transcriptase; Variability

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CODON; FEMALE; FRANCE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RESISTANCE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRACTICE GUIDELINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; COHORT STUDIES; DNA, COMPLEMENTARY; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FRANCE; HIV INFECTIONS; HIV-2; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 12944265178     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20296     Document Type: Article

References (44)

1. Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, Eholie S, Borget MY, Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, Nolan M, Chorba T, Heneine W, Nkengasong JN. 2003. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 17:S49-S54.
2. Bacolla A, Shih CK, Rose JM, Piras G, Warren TC, Grygon CA, Ingraham RH, Cousins RC, Greenwood DJ, Richman D, Cheng YC, Griffin JA. 1993. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs. J Biol Chem 268:16571-16577.
3. Balzarini J, Wedgwood O, Kruining J, Pelemans H, Heijtink R, De Clercq E, McGuigan C. 1996. Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun 225:363-369.
4. Balzarini J, Kruining J, Wedgwood O, Pannecouque C, Aquaro S, Perno CF, Naesens L, Witvrouw M, Heijtink R, De Clercq E, McGuigan C. 1997. Conversion of 2′,3′-dideoxyadenosine (ddA) and 2′,3′-didehydro- 2′,3′-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Lett 410:324-328.
5. Bock PJ, Markovitz DM. 2001. Infection with HIV-2. AIDS 15:S35-S45.
6. Brandin E, Lindborg L, Gyllensten K, Brostrom C, Hagberg L, Gisslen M, Tuvesson B, Blaxhult A, Albert J. 2003. pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 19:543-550.
7. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C, et al. 1986. Isolation of a new human retrovirus from West African patients with AIDS. Science 233:343-346.
8. Coates JA, Cammack N, Jenkinson HJ, Jowett AJ, Jowett MI, Pearson BA, Penn CR, Rouse PL, Viner KC, Cameron JM. 1992. (-)-2′-deoxy-3′- thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 36:733-739.
9. Colson P, Henry M, Simon S, Tivoli N, Gallais H, Moreau J, Gastaut JA, Tamalet C. 2004a. High prevalence of HBV genotype E infection in HIV-2-infected patients living in southeastern France, 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA: abstr. 833.
10. Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, Gastaut JA, Moreau J, Tamalet C. 2004b. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol 42:570-577.
11. Condra JH, Emini EA, Gotlib L, Graham DJ, Schlabach AJ, Wolfgang JA, Colonno RJ, Sardana W. 1992. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother 36:1441-1446.
12. Cox SW, Aperia K, Albert J, Wahren B. 1994. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Res Hum Retroviruses 10:1725-1729.
13. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 75:4771-4779.
14. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mêle A, Paumgartner G, Pietrangelo A, Rodes J, Rosenberg W, Valla D, EASL Jury. 2003. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 39: S3-S25.
15. de Ronde A, van Dooren M, van Der Hoek L, Bouwhuis D, de Rooij E, van Gemen B, de Boer R, Goudsmit J. 2001. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 75:595-602.
16. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W. 2001. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci USA 98:13907-13912.
17. Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M. 1987. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 326:662-669.
18. Hizi A, Tal R, Shaharabany M, Currens MJ, Boyd MR, Hughes SH, McMahon JB. 1993. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob Agents Chemother 37:1037-1042.
19. Houston SC, Miedzinski LJ, Mashinter LD. 2002. Rapid progression of CD4 cell decline and subsequent response to salvage therapy in HIV-2 infection. AIDS 16:1189-1191.
20. Kosalaraksa P, Kavlick MF, Maroun V, Le R, Mitsuya H. 1999. Comparative fitness of multi-dideoxyncleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J Virol 73:5356-5363.
21. Perach M, Rubinek T, Hizi A. 1995. Resistance to nucleoside analogs of selective mutants of human immunodeficiency virus type 2 reverse transcriptase. J Virol 69:509-512.
22. Post K, Guo J, Howard KJ, Powell MD, Miller JT, Hizi A, Le Grice SF, Levin JG. 2003. Human immunodeficiency virus type 2 reverse transcriptase activity in model systems that mimic steps in reverse transcription. J Virol 77:7623-7634.
23. Reeves JD, Doms RW. 2002. Human immunodeficiency virus type 2. J Gen Virol 83:1253-1265.
24. Reid P, MacInnes H, Cong M, Heneine W, Garcia-Lerma JG. 2004. Natural resistance of HIV-2 to zidovudine. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, abstr. 691.
25. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. 2002. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci USA 99:14410-14415.
26. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. 2003. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31:298-303.
27. Rodes B, Holguin A, Soriano V, Dourana M, Mansinho K, Antunes F, Gonzalez-Lahoz J. 2000. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 38:1370-1374.
28. Schutten M, van der Ende ME, Osterhaus AD. 2000. Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2. N Engl J Med 342:1758-1760.
29. Shafer RW, Stevenson D, Chan B. 1999. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 27:348-352.
30. Shaharabany M, Hizi A. 1992. The catalytic functions of chimeric reverse transcriptases of human immunodeficiency viruses type 1 and type 2. J Biol Chem 267:3674-3678.
31. Smith NA, Shaw T, Berry N, Vella C, Okorafor L, Taylor D, Ainsworth J, Choudhury A, Daniels RS, El-Gadi S, Fakoya A, Moyle G, Oxford J, Tedder R, O'Shea S, de Ruiter A, Breuer J. 2001. Antiretroviral therapy for HIV-2 infected patients. J Infect 42:126-133.
32. Soriano V, Gomes P, Heneine W, Holguin A, Doruana M, Antunes R, Mansinho K, Switzer WM, Araujo C, Shanmugam V, Lourenco H, Gonzalez-Lahoz J, Antunes F. 2000. Human immunodeficiency virus type 2 (HIV-2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 61:111-116.
33. Tamalet C, Yahi N, Tourres C, Colson P, Quinson AM, Poizot-Martin I, Dhiver C, Fantini J. 2000. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: Incidence and association with other resistance mutations. Virology 270:310-316.
34. Tamalet C, Fantini J, Tourres C, Yahi N. 2003. Resistance of HIV-1 to multiple antiretroviral drugs in France: A 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 17:2383-2388.
35. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25:4876-4882.
36. Tisdale M, Alnadaf T, Cousens D. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 41:1094-1098.
37. Van der Ende ME, Schutten M, Ly TD, Gruters RA, Osterhaus AD. 1996. HIV-2 infection in 12 European residents: Virus characteristics and disease progression. AIDS 10:1649-1655.
38. Van der Ende ME, Guillon C, Boers PH, Ly TD, Gruters RA, Osterhaus AD, Schutten M. 2000. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 25:11-18.
39. Van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD, Schutten M. 2003. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 17:S55-S61.
40. Van Rompay KK, Greenier JL, Marthas ML, Otsyula MG, Tarara RP, Miller CJ, Pedersen NC. 1997. A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Antimicrob Agents Chemother 41:278-283.
41. Van Vaerenbergh K, Van Laethem K, Albert J, Boucher CA, Clotet B, Floridia M, Gerstoft J, Hejdeman B, Nielsen C, Pannecouque C, Perrin L, Pirillo MF, Ruiz L, Schmit JC, Schneider F, Schoolmeester A, Schuurman R, Stellbrink HJ, Stuyver L, Van Lunzen J, Van Remoortel B, Van Wijngaerden E, Vella S, Witvrouw M, Yerly S, De Clercq E, Destmyer J, Vandamme AM. 2000. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 44:2109-2117.
42. Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM. 1999. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 13:1477-1483.
43. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. 2004. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and postexposure prophylaxis. Antivir Ther 9:57-65.
44. Yahi N, Tamalet C, Tourres C, Tivoli N, Fantini J. 2000. Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. J Biomed Sci 7:507-513.